Alternatives to Topical Glaucoma Medication for Glaucoma Management

References

• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. doi:10.1001/archopht.120.6.701
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–1953.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279.
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295–1304. doi:10.1016/S0140-6736(14)62111-5
   PubMed Web of Science ®Google Scholar
• Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994;101(10):1651–1656.
   PubMed Web of Science ®Google Scholar
• Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-Up Study: 7. Am J Ophthalmol. 1995;120(6):718–731.
   PubMed Web of Science ®Google Scholar
• Radcliffe N, Shah M, Samuelson TW. Challenging the “Topical Medications-First” Approach to Glaucoma: a Treatment Paradigm in Evolution. Ophthalmol Therapy. 2023.
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598–606.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21(4):410–414. doi:10.5301/EJO.2010.6112
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t. Ophthalmology. 2011;118(12):2398–2402. doi:10.1016/j.ophtha.2011.05.013
   PubMed Web of Science ®Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–961.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116(2):176–181.
   PubMed Web of Science ®Google Scholar
• Kass MA, Gordon M, Morley RE Jr, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;103(2):188–193. doi:10.1016/s0002-9394(14)74225-4
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2020;127(4):477–483. doi:10.1016/j.ophtha.2019.10.022
   PubMed Web of Science ®Google Scholar
• Rajurkar K, Dubey S, Gupta PP, John D, Chauhan L. Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India. J Curr Ophthalmol. 2018;30(2):125–129. doi:10.1016/j.joco.2017.09.002
   PubMed Web of Science ®Google Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30–6. doi:10.1016/j.ophtha.2009.06.024
   PubMed Web of Science ®Google Scholar
• Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opinion Ophthalmol. 2006;17(2):190–195.
   PubMed Web of Science ®Google Scholar
• Budenz DL. A clinician’s guide to the assessment and management of nonadherence in glaucoma. Ophthalmology. 2009;116(11 Suppl):S43–7. doi:10.1016/j.ophtha.2009.06.022
   PubMed Web of Science ®Google Scholar
• Asefzadeh B, Rett D, Pogoda TK, Selvin G, Cavallerano A. Glaucoma medication adherence in veterans and influence of coexisting chronic disease. J Glaucoma. 2014;23(4):240–245. doi:10.1097/IJG.0000000000000044
   PubMed Web of Science ®Google Scholar
• Handforth A, Parker GA. Conditions Associated with Essential Tremor in Veterans: a Potential Role for Chronic Stress. Tremor Other Hyperkinet Mov. 2018;8:517. doi:10.7916/D8VD8FF5
   PubMed Web of Science ®Google Scholar
• Poleon S, Racette L, Fifolt M, Schoenberger-Godwin YM, Abu SL, Twa MD. Patient and Provider Perspectives on Glaucoma Treatment Adherence: a Delphi Study in Urban Alabama. Optom Vis Sci. 2021;98(9):1085–1093. doi:10.1097/OPX.0000000000001776
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Robin AL, Blachley T, et al. The Most Common Barriers to Glaucoma Medication Adherence: a Cross-Sectional Survey. Ophthalmology. 2015;122(7):1308–1316. doi:10.1016/j.ophtha.2015.03.026
   PubMed Web of Science ®Google Scholar
• Yochim BP, Mueller AE, Kane KD, Kahook MY. Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma. J Glaucoma. 2012;21(4):250–254. doi:10.1097/IJG.0b013e3182071b7e
   PubMed Web of Science ®Google Scholar
• Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101(5):515–523.
   PubMed Web of Science ®Google Scholar
• Tatham AJ, Sarodia U, Gatrad F, Awan A. Eye drop instillation technique in patients with glaucoma. Eye. 2013;27(11):1293–1298. doi:10.1038/eye.2013.187
   PubMed Web of Science ®Google Scholar
• Usgaonkar U, Zambaulicar V, Shetty A. Subjective and objective assessment of the eye drop instillation technique: a hospital-based cross-sectional study. Indian J Ophthalmol. 2021;69(10):2638–2642. doi:10.4103/ijo.IJO_3333_20
   PubMed Web of Science ®Google Scholar
• Gomes BF, Paredes AF, Madeira N, Moraes HV Jr, Santhiago MR. Assessment of eye drop instillation technique in glaucoma patients. Arquivos Brasileiros De Oftalmologia. 2017;80(4):238–241. doi:10.5935/0004-2749.20170058
   PubMed Web of Science ®Google Scholar
• Kashiwagi K, Matsuda Y, Ito Y, et al. Investigation of visual and physical factors associated with inadequate instillation of eyedrops among patients with glaucoma. PLoS One. 2021;16(5):e0251699. doi:10.1371/journal.pone.0251699
   PubMed Web of Science ®Google Scholar
• Gupta R, Patil B, Shah BM, Bali SJ, Mishra SK, Dada T. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012;21(3):189–192. doi:10.1097/IJG.0b013e31820bd2e1
   PubMed Web of Science ®Google Scholar
• Stone JL, Robin AL, Novack GD, Covert DW, Cagle GD. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol. 2009;127(6):732–736.
   PubMedGoogle Scholar
• Schwartz GF, Hollander DA, Williams JM. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2013;29(11):1515–1522. doi:10.1185/03007995.2013.833898
   PubMed Web of Science ®Google Scholar
• Rees G, Leong O, Crowston JC, Lamoureux EL. Intentional and Unintentional Nonadherence to Ocular Hypotensive Treatment in Patients with Glaucoma. Ophthalmology. 2010. doi:10.1016/j.ophtha.2009.10.038
   PubMed Web of Science ®Google Scholar
• Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework. J Psychosomatic Res. 2008;64(1):41–46. doi:10.1016/j.jpsychores.2007.05.004
   PubMed Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–1516. doi:10.1016/S0140-6736(18)32213-X
   PubMed Web of Science ®Google Scholar
• Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t. J Glaucoma. 2012;21(7):460–468. doi:10.1097/IJG.0b013e318218287f
   PubMed Web of Science ®Google Scholar
• Musch DC, Niziol LM, Gillespie BW, Lichter PR Stepped Medication Use, Associated Symptoms, and Treatment Failure among Participants in the Medication Arm of the Collaborative Initial Glaucoma Treatment Study. presented at: ARVO; 2018; Honolulu, HA.
   Google Scholar
• Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13(2):130–136.
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Managed Care. 2009;15(6):e22–33.
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863–868.
   PubMed Web of Science ®Google Scholar
• Labbe A, Terry O, Brasnu E, Van Went C, Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012;31(9):994–999. doi:10.1097/ICO.0b013e31823f8cb6
   PubMed Web of Science ®Google Scholar
• O’Hare F, Ghosh S, Lamoureux E, Vajpayee RB, Crowston JG. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012;40(7):675–681. doi:10.1111/j.1442-9071.2012.02781.x
   PubMed Web of Science ®Google Scholar
• Valente C, Iester M, Corsi E, Rolando M. Symptoms and signs of tear film dysfunction in glaucomatous patients. J Ocul Pharmacol Ther. 2011;27(3):281–285. doi:10.1089/jop.2010.0133
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355. doi:10.1097/IJG.0b013e31815c5f4f
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi:10.1097/ICO.0b013e3181c325b2
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, Raimondi M, Lanteri S, Bianchi PE. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23(3):296–302. doi:10.5301/ejo.5000220
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular Surface Disease and Quality of Life in Patients With Glaucoma. Am J Ophthalmol. 2011. doi:10.1016/j.ajo.2011.05.033
   PubMedGoogle Scholar
• Kolko M, Gazzard G, Baudouin C, et al. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. Ocular Surface. 2023;29:456–468. doi:10.1016/j.jtos.2023.05.012
   PubMed Web of Science ®Google Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2009;4:59–64.
   Google Scholar
• Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446–1454.
   PubMedGoogle Scholar
• Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Progress Retinal Eye Res. 2010;29(4):312–334. doi:10.1016/j.preteyeres.2010.03.001
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye. 2022;36(2):361–368. doi:10.1038/s41433-021-01668-x
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vision. 2011;17:1806–1813.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol. 2011;95(10):1466–1469. doi:10.1136/bjophthalmol-2011-300012
   PubMed Web of Science ®Google Scholar
• Stringham J, Ashkenazy N, Galor A, Wellik SR. Barriers to Glaucoma Medication Compliance Among Veterans: dry Eye Symptoms and Anxiety Disorders. Eye Contact Lens. 2017. doi:10.1097/ICL.0000000000000301
   Web of Science ®Google Scholar
• Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19(4):572–579. doi:10.1177/112067210901900409
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, Bianchi PE. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther. 2013;29(4):390–394. doi:10.1089/jop.2011.0159
   PubMed Web of Science ®Google Scholar
• Johnson DH, Yoshikawa K, Brubaker RF, Hodge DO. The effect of long-term medical therapy on the outcome of filtration surgery. Am J Ophthalmol. 1994;117(2):139–148.
   PubMed Web of Science ®Google Scholar
• Ergin A, Ornek K, Gullu R, Bulcun E, Ekici M, Ekici A. Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma. J Ocul Pharmacol Ther. 2009;25(5):463–466.
   PubMed Web of Science ®Google Scholar
• Han JA, Frishman WH, Wu Sun S, Palmiero PM, Petrillo R. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev. 2008;16(2):95–108.
   PubMed Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension. Ophthalmology. 2023;130(2):139–151. doi:10.1016/j.ophtha.2022.09.009
   PubMed Web of Science ®Google Scholar
• Malihi M, Moura Filho ER, Hodge DO, Sit AJ. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t. Ophthalmology. 2014;121(1):134–141. doi:10.1016/j.ophtha.2013.09.003
   PubMed Web of Science ®Google Scholar
• Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138(3):389–395.
   PubMed Web of Science ®Google Scholar
• Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Survey Ophthalmol. 2004;49(Suppl 1):S26–35.
   PubMedGoogle Scholar
• Nouri-Mahdavi K, Medeiros FA, Weinreb RN. Fluctuation of intraocular pressure as a predictor of visual field progression. Arch Ophthalmol. 2008;126(8):1168–1169. doi:10.1001/archopht.126.8.1168
   PubMedGoogle Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111(9):1627–1635. doi:10.1016/j.ophtha.2004.02.017
   PubMed Web of Science ®Google Scholar
• Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134–142.
   PubMed Web of Science ®Google Scholar
• Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(7):1123–1129 e3. doi:10.1016/j.ophtha.2007.10.031
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of Long-term Progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007.
   Web of Science ®Google Scholar
• Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(2):205–209.
   PubMed Web of Science ®Google Scholar
• Posarelli C, Ortenzio P, Ferreras A, et al. Twenty-Four-Hour Contact Lens Sensor Monitoring of Aqueous Humor Dynamics in Surgically or Medically Treated Glaucoma Patients. J Ophthalmol. 2019;2019:9890831. doi:10.1155/2019/9890831
   PubMed Web of Science ®Google Scholar
• Muniesa MJ, Ezpeleta J, Benitez I. Fluctuations of the Intraocular Pressure in Medically Versus Surgically Treated Glaucoma Patients by a Contact Lens Sensor. Am J Ophthalmol. 2019;203:1–11. doi:10.1016/j.ajo.2019.02.003
   PubMed Web of Science ®Google Scholar
• Caprioli J, Kim JH, Friedman DS, et al. Special Commentary: supporting Innovation for Safe and Effective Minimally Invasive Glaucoma Surgery: summary of a Joint Meeting of the American Glaucoma Society and the Food and Drug Administration, Washington, DC, February 26, 2014. Ophthalmology. 2015;122(9):1795–1801. doi:10.1016/j.ophtha.2015.02.029
   PubMed Web of Science ®Google Scholar
• Gupta D, Ehrlich JR, Newman-Casey PA, Stagg B. Cost-Related Medication Nonadherence in a Nationally Representative US Population with Self-Reported Glaucoma. Ophthalmol Glaucoma. 2021;4(2):126–130. doi:10.1016/j.ogla.2020.08.010
   PubMedGoogle Scholar
• Delavar A, Radha Saseendrakumar B, Weinreb RN, Baxter SL. Racial and Ethnic Disparities in Cost-Related Barriers to Medication Adherence Among Patients With Glaucoma Enrolled in the National Institutes of Health All of Us Research Program. JAMA Ophthalmol. 2022;140(4):354–361. doi:10.1001/jamaophthalmol.2022.0055
   PubMed Web of Science ®Google Scholar
• Wittenborn JS, Rein DB. Cost-effectiveness of glaucoma interventions in Barbados and Ghana. Optom Vis Sci. 2011;88(1):155–163. doi:10.1097/OPX.0b013e3181fc30f3
   PubMed Web of Science ®Google Scholar
• Realini T, Olawoye O, Kizor-Akaraiwe N, Manji S, Sit A. The Rationale for Selective Laser Trabeculoplasty in Africa. Asia Pac J Ophthalmol. 2018;7(6):387–393. doi:10.22608/APO.2018271
   PubMed Web of Science ®Google Scholar
• Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983;220(4596):524–527.
   PubMed Web of Science ®Google Scholar
• Parrish J, Deutsch T. Laser photomedicine. IEEE J Quantum Electronics. 1984;20:1386–1396.
   Web of Science ®Google Scholar
• Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995;60(4):359–371.
   PubMed Web of Science ®Google Scholar
• Nagar M, Ogunyomade A, O’Brart DP, Howes F, Marshall J. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89(11):1413–1417. doi:10.1136/bjo.2004.052795
   PubMed Web of Science ®Google Scholar
• McIlraith I, Strasfeld M, Colev G, Hutnik CM. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma. 2006;15(2):124–130.
   PubMed Web of Science ®Google Scholar
• Lai JS, Chua JK, Tham CC, Lam DS. Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clin Exp Ophthalmol. 2004;32(4):368–372.
   PubMed Web of Science ®Google Scholar
• Realini T, Shillingford-Ricketts H, Burt D, Balasubramani GK. West Indies Glaucoma Laser Study (WIGLS) 3. Anterior Chamber Inflammation Following Selective Laser Trabeculoplasty in Afro-Caribbeans with Open-Angle Glaucoma. J Glaucoma. 2019. doi:10.1097/IJG.0000000000001250
   PubMed Web of Science ®Google Scholar
• Zhang L, Weizer JS, Musch DC. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. Cochrane Database Sys Rev. 2017;2:CD010746. doi:10.1002/14651858.CD010746.pub2
   Web of Science ®Google Scholar
• Realini T. Selective laser trabeculoplasty: a review. J Glaucoma. 2008;17(6):497–502. doi:10.1097/IJG.0b013e31817d2386
   PubMed Web of Science ®Google Scholar
• Song J. Complications of selective laser trabeculoplasty: a review. Clin Ophthalmol. 2016;10:137–143. doi:10.2147/OPTH.S84996
   PubMed Web of Science ®Google Scholar
• Ozkok A, Tamcelik N, Ucar Comlekoglu D, Iskeleli G. Corneal decompensation after selective laser trabeculoplasty. Case Rep Ophthalmol Med. 2014;2014:851971. doi:10.1155/2014/851971
   PubMedGoogle Scholar
• De Keyser M, De Belder M, De Groot V. Quality of life in glaucoma patients after selective laser trabeculoplasty. Int J Ophthalmol. 2017;10(5):742–748. doi:10.18240/ijo.2017.05.14
   PubMed Web of Science ®Google Scholar
• Ang GS, Fenwick EK, Constantinou M, et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial. Br J Ophthalmol. 2020;104(6):813–821. doi:10.1136/bjophthalmol-2018-313396
   PubMed Web of Science ®Google Scholar
• Kass MA, Gordon MO, Gao F, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol. 2010;128(3):276–287. doi:10.1001/archophthalmol.2010.20
   PubMedGoogle Scholar
• Hyman LG, Komaroff E, Heijl A, Bengtsson B, Leske MC. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005;112(9):1505–1513.
   PubMed Web of Science ®Google Scholar
• Jones L, Garway-Heath DF, Azuara-Blanco A, Crabb DP. United Kingdom Glaucoma Treatment Study I. Are Patient Self-Reported Outcome Measures Sensitive Enough to Be Used as End Points in Clinical Trials?: evidence from the United Kingdom Glaucoma Treatment Study. Ophthalmology. 2019;126(5):682–689. doi:10.1016/j.ophtha.2018.09.034
   PubMed Web of Science ®Google Scholar
• Bartlett VL, Liu P, Dhruva SS, Shah ND, Bollinger KE, Ross JS. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017. J Manag Care Spec Pharm. 2020;26(4):562–567. doi:10.18553/jmcp.2020.26.4.562
   PubMed Web of Science ®Google Scholar
• Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton DW. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol. 2012;130(4):497–505. doi:10.1001/archophthalmol.2011.2727
   PubMedGoogle Scholar
• Friedman DS, Wolfs RC, O’Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532–538.
   PubMedGoogle Scholar
• King C, Sherwin JC, Ratnarajan G, Salmon JF. Twenty-year outcomes in patients with newly diagnosed glaucoma: mortality and visual function. Br J Ophthalmol. 2018;102(12):1663–1666. doi:10.1136/bjophthalmol-2017-311595
   PubMed Web of Science ®Google Scholar
• Ansari E. 10-year outcomes of first-line selective laser trabeculoplasty (SLT) for primary open-angle glaucoma (POAG). Graefes Arch Clin Exp Ophthalmol. 2021;259(6):1597–1604. doi:10.1007/s00417-021-05098-z
   PubMed Web of Science ®Google Scholar
• Realini T, Shillingford-Ricketts H, Burt D, Balasubramani GK. Long-Term Outcomes of Selective Laser Trabeculoplasty for Open-Angle Glaucoma in the Caribbean. Am J Ophthalmol. 2021;232:83–89. doi:10.1016/j.ajo.2021.06.012
   PubMed Web of Science ®Google Scholar
• Belkin M GLAUrious, a multicentre, randomised, controlled non-inferiority study of direct selective laser trabeculoplasty in open angle glaucoma. presented at: ARVO; 2022; Denver, CO.
   Google Scholar
• Realini T, Gazzard G, Latina M, Kass M. Low-energy Selective Laser Trabeculoplasty Repeated Annually: rationale for the COAST Trial. J Glaucoma. 2021;30(7):545–551. doi:10.1097/IJG.0000000000001788
   PubMed Web of Science ®Google Scholar
• Ma A, Yu SWY, Wong JKW. Micropulse laser for the treatment of glaucoma: a literature review. Survey Ophthalmol. 2019;64(4):486–497. doi:10.1016/j.survophthal.2019.01.001
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Evidence Reviews for Selective Laser Trabeculoplasty in Ocular Hypertension or Chronic Open-Angle Glaucoma Adult Patients: Glaucoma: Diagnosis and Management: Evidence Review A. National Institute for Health and Care Excellence; 2022.
   Google Scholar
• Ghanchi F, Bourne R, Downes SM, et al. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. Eye. 2022;36(6):1154–1167. doi:10.1038/s41433-021-01766-w
   PubMed Web of Science ®Google Scholar
• Gaballa SA, Kompella UB, Elgarhy O, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021;11(3):866–893. doi:10.1007/s13346-020-00843-z
   PubMed Web of Science ®Google Scholar
• Al-Qaysi ZK, Beadham IG, Schwikkard SL, Bear JC, Al-Kinani AA, Alany RG. Sustained release ocular drug delivery systems for glaucoma therapy. Expert Opinion Drug Delivery. 2023. doi:10.1080/17425247.2023.2219053
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. NDA Approval Letter (Durysta). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211911Orig1s000ltr.pdf. Accessed June 4, 2020.
   Google Scholar
• Muniesa M, Ezpeleta J, Benitez I. Fluctuations of the Intraocular Pressure in Medically Versus Surgically Treated Glaucoma Patients by a Contact Lens Sensor. Am J Ophthalmol. 2019;207:429–430. doi:10.1016/j.ajo.2019.08.008
   PubMed Web of Science ®Google Scholar
• Kwatra D, Mitra AK. Drug delivery in ocular diseases: barriers and strategies. World J Pharmacol. 2013;2:78–83.
   Google Scholar
• Kompella UB, Hartman RR, Patil MA. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Progress Retinal Eye Res. 2021;82:100901. doi:10.1016/j.preteyeres.2020.100901
   PubMed Web of Science ®Google Scholar
• Singh IP, Doan L, Stephens K, Unser D, Katz J, Navratil T Outcomes of the Prospective Randomized Controlled Multicenter Phase III Trials of Intracameral Travoprost-Eluting Implants versus Topical Timolol. presented at: American Glaucoma Society Annual Meeting; 2023; Austin, TX.
   Google Scholar
• Katz J, Sarkisian SR, Voskanyan L, et al. Results of the Prospective, Randomized, Controlled, Multi-center Phase 3 Trials of the Travoprost Intraocular Implant versus Topical Timolol presented at: ARVO Annual Meeting; 2023; New Orleans, LA.
   Google Scholar
• Berdahl J, Doan L, Stephens K, Unser D, Katz J, Navratil T Outcomes of the Prospective Randomized Controlled Multicenter Phase III Trials of iDose® TR versus Topical Timolol. presented at: ASCRS Annual Meeting; 2023; San Diego, CA.
   Google Scholar
• Seal JR, Robinson MR, Burke J, Bejanian M, Coote M, Attar M. Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues. J Ocul Pharmacol Ther. 2019;35(1):50–57. doi:10.1089/jop.2018.0067
   PubMed Web of Science ®Google Scholar
• Kouri C. Results for iDose Exchange Trial Show Good Safety and Tolerability. Ophthalmol Management. 2023;27:6.
   Google Scholar
• Glaukos Investor Relations Presentation 5/17/23. Available from: https://investors.glaukos.com/investors/events-and-presentations/presentations/default.aspx. Accessed July 24, 2023.
   Google Scholar
• Mohammadi M, Patel K, Alaie SP, et al. Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery. Acta Biomater. 2018;73:90–102. doi:10.1016/j.actbio.2018.04.037
   PubMed Web of Science ®Google Scholar
• Blizzard CD, Akasheh D, Cheung M, Vantipalli S, Jarrett P. Polymers for retinal drug delivery. Retinal Phys. 2023;28–31.
   Google Scholar
• Weinreb RN, Bacharach J, Brubaker JW, et al. Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies. J Ocul Pharmacol Ther. 2023;39(1):55–62. doi:10.1089/jop.2022.0137
   PubMed Web of Science ®Google Scholar
• Gautam M, Gupta R, Singh P, et al. Intracameral Drug Delivery: a Review of Agents, Indications, and Outcomes. J Ocul Pharmacol Ther. 2023;39(2):102–116. doi:10.1089/jop.2022.0144
   PubMed Web of Science ®Google Scholar
• Cong YY, Fan B, Zhang ZY, Li GY. Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics. Int Ophthalmol. 2023. doi:10.1007/s10792-023-02637-x
   PubMed Web of Science ®Google Scholar
• Mofidfar M, Abdi B, Ahadian S, et al. Drug delivery to the anterior segment of the eye: a review of current and future treatment strategies. Int J Pharm. 2021;607:120924. doi:10.1016/j.ijpharm.2021.120924
   PubMed Web of Science ®Google Scholar
• Belamkar A, Harris A, Zukerman R, et al. Sustained release glaucoma therapies: novel modalities for overcoming key treatment barriers associated with topical medications. Ann Med. 2022;54(1):343–358. doi:10.1080/07853890.2021.1955146
   PubMed Web of Science ®Google Scholar
• Gedde SJ, Feuer WJ, Lim KS, et al. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up. Ophthalmology. 2020;127(3):333–345. doi:10.1016/j.ophtha.2019.10.002
   PubMed Web of Science ®Google Scholar
• Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789–803.
   PubMed Web of Science ®Google Scholar
• Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153(5):804–814. doi:10.1016/j.ajo.2011.10.024
   PubMed Web of Science ®Google Scholar
• Boland MV, Corcoran KJ, Lee AY. Changes in Performance of Glaucoma Surgeries 1994 through 2017 Based on Claims and Payment Data for United States Medicare Beneficiaries. Ophthalmol Glaucoma. 2021;4(5):463–471. doi:10.1016/j.ogla.2021.01.004
   PubMedGoogle Scholar
• Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent Technologies. Available from: https://www.businesswire.com/news/home/20210823005049/en/Glaukos-Announces-Market-Leading-Clinical-Milestone-of-200-Peer-Reviewed-Publications-on-iStent%C2%AE-Technologies. Accessed September 7, 2023.
   Google Scholar
• Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opinion Ophthalmol. 2012;23(2):96–104. doi:10.1097/ICU.0b013e32834ff1e7
   PubMed Web of Science ®Google Scholar
• Aref AA, Parker PR, Chen MY. Microinvasive glaucoma surgeries: critical summary of clinical trial data with and without phacoemulsification. Curr Opinion Ophthalmol. 2023;34(2):146–151. doi:10.1097/ICU.0000000000000923
   PubMed Web of Science ®Google Scholar
• Birnbaum FA, Neeson C, Sola-Del Valle D. Microinvasive Glaucoma Surgery: an Evidence-Based Review. Sem Ophthalmol. 2021;36(8):772–786. doi:10.1080/08820538.2021.1903513
   PubMed Web of Science ®Google Scholar
• Vinod K, Gedde SJ. Safety profile of minimally invasive glaucoma surgery. Curr Opinion Ophthalmol. 2021;32(2):160–168. doi:10.1097/ICU.0000000000000731
   PubMed Web of Science ®Google Scholar
• Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189–206. doi:10.2147/OPTH.S80490
   PubMed Web of Science ®Google Scholar
• Ansari E. An Update on Implants for Minimally Invasive Glaucoma Surgery (MIGS). Ophthalmol Ther. 2017;6(2):233–241. doi:10.1007/s40123-017-0098-2
   PubMed Web of Science ®Google Scholar
• Radcliffe N. The case for standalone micro-invasive glaucoma surgery: rethinking the role of surgery in the glaucoma treatment paradigm. Curr Opinion Ophthalmol. 2023;34(2):138–145. doi:10.1097/ICU.0000000000000927
   PubMed Web of Science ®Google Scholar
• Khodeiry M, Sayed MS. New glaucoma drainage implants available to glaucoma surgeons. Curr Opinion Ophthalmol. 2023;34(2):176–180. doi:10.1097/ICU.0000000000000936
   PubMed Web of Science ®Google Scholar
• Sarkisian SR. Stand-alone surgery for mild to moderate glaucoma and ocular surface disease: June consultation #1. J Cataract Refract Surg. 2020;46(6):922. doi:10.1097/j.jcrs.0000000000000244
   PubMedGoogle Scholar
• Agrawal P, Bradshaw SE. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma. Ophthalmol Ther. 2018;7(1):49–73. doi:10.1007/s40123-018-0131-0
   PubMed Web of Science ®Google Scholar
• Gillmann K, Mansouri K. Minimally Invasive Glaucoma Surgery: where Is the Evidence? Asia Pac J Ophthalmol. 2020;9(3):203–214. doi:10.1097/APO.0000000000000294
   PubMed Web of Science ®Google Scholar
• Cantor L, Lindfield D, Ghinelli F, et al. Systematic Literature Review of Clinical, Economic, and Humanistic Outcomes Following Minimally Invasive Glaucoma Surgery or Selective Laser Trabeculoplasty for the Treatment of Open-Angle Glaucoma with or Without Cataract Extraction. Clin Ophthalmol. 2023;17:85–101. doi:10.2147/OPTH.S389406
   PubMed Web of Science ®Google Scholar
• Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta-analysis. PLoS One. 2017;12(8):e0183142. doi:10.1371/journal.pone.0183142
   PubMed Web of Science ®Google Scholar
• Ahmed IIK, De Francesco T, Rhee D, et al. Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm’s Canal Microstent in Combination Cataract and Glaucoma Surgery. Ophthalmology. 2022;129(7):742–751. doi:10.1016/j.ophtha.2022.02.021
   PubMed Web of Science ®Google Scholar
• Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118(3):459–467. doi:10.1016/j.ophtha.2010.07.007
   PubMed Web of Science ®Google Scholar
• Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: two-Year Results. Ophthalmology. 2019;126(6):811–821. doi:10.1016/j.ophtha.2019.03.006
   PubMed Web of Science ®Google Scholar
• Williamson BK, Vold SD, Campbell A, et al. Canaloplasty and Trabeculotomy with the OMNI System in Patients with Open-Angle Glaucoma: two-Year Results from the ROMEO Study. Clin Ophthalmol. 2023;17:1057–1066. doi:10.2147/OPTH.S407918
   PubMed Web of Science ®Google Scholar
• Terveen DC, Sarkisian SR Jr, Vold SD, et al. Canaloplasty and trabeculotomy with the OMNI((R)) surgical system in OAG with prior trabecular microbypass stenting. Int Ophthalmol. 2023;43(5):1647–1656. doi:10.1007/s10792-022-02553-6
   PubMed Web of Science ®Google Scholar
• Vold SD, Williamson BK, Hirsch L, et al. Canaloplasty and Trabeculotomy with the OMNI System in Pseudophakic Patients with Open-Angle Glaucoma: the ROMEO Study. Ophthalmol Glaucoma. 2021;4(2):173–181. doi:10.1016/j.ogla.2020.10.001
   PubMedGoogle Scholar
• Sarkisian SR Jr. Cochrane Reviews Regarding Minimally Invasive Glaucoma Surgical Techniques-Validity of Conclusions May Be Limited by Incomplete Evidence. JAMA Ophthalmol. 2022;140(2):206–207. doi:10.1001/jamaophthalmol.2021.5397
   PubMed Web of Science ®Google Scholar
• Samuelson TW, Singh IP, Williamson BK, et al. Quality of Life in Primary Open-Angle Glaucoma and Cataract: an Analysis of VFQ-25 and OSDI From the iStent inject Pivotal Trial. Am J Ophthalmol. 2021;229:220–229. doi:10.1016/j.ajo.2021.03.007
   PubMed Web of Science ®Google Scholar
• Al Habash A, Albuainain A. Long term outcome of combined phacoemulsification and excisional goniotomy with the Kahook Dual Blade in different subtypes of glaucoma. Sci Rep. 2021;11(1):10660. doi:10.1038/s41598-021-90223-5
   PubMed Web of Science ®Google Scholar
• Al Habash A, Nagshbandi AA. Quality of Life After Combined Cataract and Minimally Invasive Glaucoma Surgery in Glaucoma Patients. Clin Ophthalmol. 2020;14:3049–3056. doi:10.2147/OPTH.S276124
   PubMed Web of Science ®Google Scholar
• Armstrong JJ, Wasiuta T, Kiatos E, Malvankar-Mehta M, Hutnik CM. The Effects of Phacoemulsification on Intraocular Pressure and Topical Medication Use in Patients With Glaucoma: a Systematic Review and Meta-analysis of 3-Year Data. J Glaucoma. 2017;26:511–522. doi:10.1097/IJG.0000000000000643
   PubMed Web of Science ®Google Scholar
• Sood S, Heilenbach N, Sanchez V, Glied S, Chen S, Al-Aswad LA. Cost-Effectiveness Analysis of Minimally Invasive Trabecular Meshwork Stents with Phacoemulsification. Ophthalmol Glaucoma. 2022;5(3):284–296. doi:10.1016/j.ogla.2021.09.006
   PubMedGoogle Scholar
• Ahmed IIK, Podbielski DW, Patel V, et al. A Canadian Cost-Utility Analysis of 2 Trabecular Microbypass Stents at Time of Cataract Surgery in Patients with Mild to Moderate Open-Angle Glaucoma. Ophthalmol Glaucoma. 2020;3(2):103–113. doi:10.1016/j.ogla.2019.11.009
   PubMedGoogle Scholar
• Fea AM, Cattel F, Gandolfi S, Buseghin G, Furneri G, Costagliola C. Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy. BMC Health Services Res. 2021;21(1):824. doi:10.1186/s12913-021-06862-x
   PubMed Web of Science ®Google Scholar
• Bartelt-Hofer J, Flessa S. Comparative efficacy and cost-utility of combined cataract and minimally invasive glaucoma surgery in primary open-angle glaucoma. Int Ophthalmol. 2020;40(6):1469–1479. doi:10.1007/s10792-020-01314-7
   PubMed Web of Science ®Google Scholar
• Mader G, Ghinelli F, Torelli F, et al. The budget impact of introducing the OMNI(R) surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma. Expert Rev Pharmacoecon Outcomes Res. 2023. doi:10.1080/14737167.2023.2217357
   PubMed Web of Science ®Google Scholar
• Thompson VM, Ferguson TJ, Ahmed IIK, et al. Short-Term Safety Evaluation of a Multi-Pressure Dial: a Prospective, Open-label, Non-randomized Study. Ophthalmol Ther. 2019;8(2):279–287. doi:10.1007/s40123-019-0181-y
   PubMed Web of Science ®Google Scholar
• Faehnle M. Magnetic Therapy of Glaucoma. J Eye Dis Disorders. 2022;7:1046.
   Google Scholar
• Posarelli C, Covello G, Bendinelli A, Fogagnolo P, Nardi M, Figus M. High-intensity focused ultrasound procedure: the rise of a new noninvasive glaucoma procedure and its possible future applications. Survey Ophthalmol. 2019;64(6):826–834. doi:10.1016/j.survophthal.2019.05.001
   PubMed Web of Science ®Google Scholar